{"denoms":[{"counts":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"21"},{"groupId":"BG003","value":"10"},{"groupId":"BG004","value":"14"},{"groupId":"BG005","value":"20"},{"groupId":"BG006","value":"10"},{"groupId":"BG007","value":"10"},{"groupId":"BG008","value":"9"},{"groupId":"BG009","value":"0"},{"groupId":"BG010","value":"116"}],"units":"Participants"}],"groups":[{"description":"Group 1 - Recurrent or Refractory Hepatoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"BG000","title":"Group 1 - Recurrent or Refractory Hepatoblastoma"},{"description":"Group 2 - Recurrent or Refractory Synovial Sarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"BG001","title":"Group 2 - Recurrent or Refractory Synovial Sarcoma"},{"description":"Group 3 - Recurrent or Refractory Rhabdomyosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"BG002","title":"Group 3 - Recurrent or Refractory Rhabdomyosarcoma"},{"description":"Group 4 - Recurrent or Refractory Adrenocortical Carcinoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"BG003","title":"Grp 4-Recurrent or Refractory Adrenocortical Carcinoma"},{"description":"Group 5 - Recurrent or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"BG004","title":"Grp 5-Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor"},{"description":"Group 6 - Recurrent or Refractory Neuroblastoma -MIBG Positive Without Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"BG005","title":"Grp 6 - Neuroblastoma-MIBG Positive Without Measurable Disease"},{"description":"Group 7 - Recurrent or Refractory Neuroblastoma -With Measurable Disease. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"BG006","title":"Grp 7-Neuroblastoma With Measurable Disease"},{"description":"Group 8 - Recurrent Osteosarcoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"BG007","title":"Group 8 - Recurrent Osteosarcoma"},{"description":"Group 9 - Recurrent or Refractory Wilms Tumor. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"BG008","title":"Group 9 - Recurrent or Refractory Wilms Tumor"},{"description":"Group 10 - Recurrent or Refractory Retinoblastoma. Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.\n\ncixutumumab: Given IV\n\nlaboratory biomarker analysis: Correlative studies","id":"BG009","title":"Group 10 - Recurrent or Refractory Retinoblastoma"},{"description":"Total of all reporting groups","id":"BG010","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"16"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"18"},{"groupId":"BG006","value":"7"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"9"},{"groupId":"BG010","value":"93"}]}],"title":"<=18 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"0"},{"groupId":"BG010","value":"23"}]}],"title":"Between 18 and 65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG010","value":"0"}]}],"title":">=65 years"}],"paramType":"NUMBER","title":"Age, Categorical","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"2","upperLimit":"7","value":"3"},{"groupId":"BG001","lowerLimit":"12","upperLimit":"26","value":"17.5"},{"groupId":"BG002","lowerLimit":"3","upperLimit":"22","value":"14"},{"groupId":"BG003","lowerLimit":"10","upperLimit":"29","value":"14"},{"groupId":"BG004","lowerLimit":"8","upperLimit":"28","value":"17"},{"groupId":"BG005","lowerLimit":"2","upperLimit":"30","value":"10.5"},{"groupId":"BG006","lowerLimit":"4","upperLimit":"26","value":"14.5"},{"groupId":"BG007","lowerLimit":"3","upperLimit":"24","value":"14.5"},{"groupId":"BG008","lowerLimit":"4","upperLimit":"14","value":"7"},{"groupId":"BG010","lowerLimit":"2","upperLimit":"30","value":"13"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"6"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"9"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"8"},{"groupId":"BG010","value":"55"}]}],"title":"Female"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"7"},{"groupId":"BG008","value":"1"},{"groupId":"BG010","value":"61"}]}],"title":"Male"}],"paramType":"NUMBER","title":"Gender","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"2"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"1"},{"groupId":"BG010","value":"15"}]}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"14"},{"groupId":"BG005","value":"18"},{"groupId":"BG006","value":"8"},{"groupId":"BG007","value":"9"},{"groupId":"BG008","value":"7"},{"groupId":"BG010","value":"96"}]}],"title":"Not Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"},{"groupId":"BG010","value":"5"}]}],"title":"Unknown or Not Reported"}],"paramType":"NUMBER","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG010","value":"0"}]}],"title":"American Indian or Alaska Native"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG010","value":"5"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG010","value":"0"}]}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"2"},{"groupId":"BG010","value":"15"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"16"},{"groupId":"BG006","value":"6"},{"groupId":"BG007","value":"6"},{"groupId":"BG008","value":"6"},{"groupId":"BG010","value":"80"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG010","value":"0"}]}],"title":"More than one race"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"1"},{"groupId":"BG010","value":"16"}]}],"title":"Unknown or Not Reported"}],"paramType":"NUMBER","title":"Race (NIH/OMB)","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"9"},{"groupId":"BG004","value":"14"},{"groupId":"BG005","value":"19"},{"groupId":"BG006","value":"9"},{"groupId":"BG007","value":"10"},{"groupId":"BG008","value":"8"},{"groupId":"BG010","value":"108"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG010","value":"2"}]}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"1"},{"groupId":"BG010","value":"6"}]}],"title":"Australia"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}],"populationDescription":"Group 10, Recurrent or Refractory Retinoblastoma no patients were enrolled."}